or Try an Advanced Search...

    Glucagon Like Peptide 1 Stocks List

    Symbol Grade Name % Change
    VANI F Vivani Medical, Inc. 3.14
    ORMP F Oramed Pharmaceuticals Inc. -0.42
    NVO F Novo Nordisk A/S -1.30
    THNR D Amplify Weight Loss Drug & Treatment ETF -0.27
    View As Page of Charts
    Related Industries: Biotechnology Medical Devices
    Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones IBD 50 Implant Inflammation Integrated Security

    Related ETFs - A few ETFs which own one or more of the above listed Glucagon Like Peptide 1 stocks.

    Symbol Grade Name Weight
    EDEN D iShares MSCI Denmark Capped ETF 22.75
    OZEM D Roundhill GLP-1 & Weight Loss ETF 20.43
    THNR D Amplify Weight Loss Drug & Treatment ETF 12.82
    IGTR C Innovator Gradient Tactical Rotation Strategy ETF 8.81
    PPH D Market Vectors Pharmaceutical ETF 8.63
    View all Glucagon Like Peptide 1 ETFs...
    Compare ETFs
    Compare EDEN to THNR Compare OZEM to PPH Compare THNR to IGTR

        Glucagon Like Peptide 1 Stocks Recent News

        Date Stock Title
        Oct 2 NVO European Equities Close Mostly Higher in Wednesday Trading; Euro Area Unemployment Unchanged in August
        Oct 2 NVO Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
        Oct 2 NVO Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn’t a Problem.
        Oct 2 NVO Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
        Oct 2 NVO Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
        Oct 2 NVO Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
        Oct 1 NVO Novo Nordisk (NVO) Stock Moves -0.89%: What You Should Know
        Oct 1 NVO U.S. port strike expected to have limited impact on healthcare supply chain: HHS
        Oct 1 NVO Novo Nordisk has mitigation plans to minimize disruption from port strikes, CNBC reports
        Sep 30 NVO Novo Nordisk (NVO) Poised for 23.3% Upside as Obesity Market Expands and Clinical Trials Impress
        Sep 30 NVO Is Novo Nordisk A/S (NYSE:NVO) The Top Global Stock To Buy Now?
        Sep 29 NVO Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
        Sep 29 NVO 'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
        Sep 28 NVO 15 Unhealthiest Countries in Europe
        Sep 28 NVO Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
        Sep 28 NVO Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
        Sep 27 NVO Novo Nordisk stock closes lower, analyst warns about Wegovy sales
        Sep 27 NVO Top Midday Stories: Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug; Novo Nordisk Shares Drop After Analyst's Sales Concerns
        Sep 27 NVO Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
        Sep 27 NVO Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
        Related Industries: Biotechnology Medical Devices
        Related Stock Lists: Diabetes Peptide Hormones Endocrine System Insulin Medicine Anti Diabetic Drugs Biopharmaceutical Chronic Disease Diabetes Care Gastrointestinal Glucagon Growth Hormone Growth Hormone Therapy Haemophilia Hormone Therapy Hormones IBD 50 Implant Inflammation Integrated Security
        Glucagon Like Peptide 1

        Glucagon-like peptide 1 (GLP-1) is a hormone that is produced in the gut and released in response to food intake. It stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and increases satiety. GLP-1 is a key regulator of glucose homeostasis and is used as a treatment for type 2 diabetes.

        Browse All Tags